Cryoport, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cryoport, Inc. (NASDAQ: CYRX) on March 21, 2022, covering events that occurred on March 15, 2022. The filing addresses Item 5.02 regarding the departure, election, or appointment of certain officers and their compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive employment agreements and does not contain financial performance data.
Material Changes
The primary material changes reported are the formalization and amendment of executive employment contracts:
- Dr. Mark Sawicki: Entered into a new written employment agreement as Chief Scientific Officer of Cryoport, Inc. and CEO of Cryoport Systems, LLC. Prior to this, he did not have a written agreement. The agreement has an initial term of three years.
- Mr. Jerrell W. Shelton: Entered into a Second Amendment to his existing employment agreement. The term was extended to June 1, 2026. The amendment expanded acceleration clauses to include all forms of equity awards (previously limited to options) in the event of termination without cause or for good reason.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard contractual terms. Key contractual provisions include:
- Severance: Dr. Sawicki is entitled to 18 months of base salary and COBRA premiums if terminated without cause or if he terminates for good reason.
- Non-Solicitation: Dr. Sawicki agreed not to solicit employees during the term of the agreement and for 18 months following termination.
- Compensation: Neither executive's base salary or participation in equity/cash bonus plans was modified by these specific agreements, though the terms of equity acceleration were clarified for Mr. Shelton.
Investor Verification Checklist
- Review Exhibit 10.1 for the full text of Dr. Sawicki's employment agreement and specific compensation details.
- Review Exhibit 10.2 for the full text of the amendment to Mr. Shelton's agreement regarding equity acceleration.
- Verify the impact of the extended term for Mr. Shelton on future compensation obligations.
- Confirm that no other undisclosed changes to executive compensation occurred concurrently.